A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Protocol No

The study drug, TNB-486, is a bispecific antibody. An antibody is a Y shaped protein used by your body's immune system to identify and destroy natural foreign objects such as bacteria, viruses and proteins. A bispecific antibody is an antibody that interacts with two different molecules in your body. In the case of TNB-486, one molecule is called CD19 that is found on your lymphoma cells. The second molecule is called CD3 and is present on your T-cells.
A T-cell is a type of white blood cell that plays an important role in the immune system. T-cells are like soldiers that search out and destroy virus infected cells, foreign cells and cancer cells. When CD3 is engaged on a T-cell, it turns the T-cell on and makes it kill whatever cell triggered the activation. Because TNB-486 sticks very strongly to your lymphoma cells, nearby T-cells should specifically attack your tumor (lymphoma) cells.

A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Participating Institutions
Froedtert Hospital